BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD6621 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD6621\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07192614-11148@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290329
DTEND;VALUE=DATE:20290330
SUMMARY:AZD6621: Phase 1/2 readout est. (NCT07192614)
DESCRIPTION:AZD6621\, phase 1/2\, Prostate Cancer.\nStudy: A Study to Learn
  How Safe AZD6621 is\, How Well it Works\, and How it Moves Throughout the
  Body Over Time\, in Adult Male Participants With Metastatic Prostate Canc
 er\nEstimated primary completion: 29 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd6621#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07192614
URL:https://assetmemo.bio/drug/azd6621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
